Understanding how Zika vaccination affects antibody responses in people with and without prior flavivirus exposure
Evaluation of Antibody Responses Elicited by Zika Vaccination in Flavivirus-naïve and -experienced Individuals
This study is looking at how the immune system reacts to the Zika virus vaccine in people who have or haven't had other similar viruses before, like dengue or yellow fever, to help improve vaccine strategies and better protect everyone from Zika and related diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project ID | NIH-11045038 on NIH RePORTER |
What this research studies
This research investigates how the immune system responds to Zika virus vaccination in individuals who have or have not been previously exposed to other flaviviruses, such as dengue or yellow fever. By analyzing the specific antibodies produced and the B cell responses, the study aims to uncover the mechanisms that lead to effective immunity. The research employs advanced technologies to sequence B cells and assess their functionality, which could inform better vaccination strategies for populations at risk. Ultimately, the goal is to enhance protection against Zika virus and related diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have never been exposed to flaviviruses as well as those with prior exposure to viruses like dengue or yellow fever.
Not a fit: Patients who are not interested in vaccination or those who have already been vaccinated against Zika may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccination strategies that provide better protection against Zika virus and related flavivirus diseases.
How similar studies have performed: Previous research has shown promising results in understanding antibody responses to flavivirus vaccinations, indicating that this approach has potential for success.
Where this research is happening
Bethesda, United States
- Henry M. Jackson Fdn for the Adv Mil/med — Bethesda, United States (Active)
Researchers
- Principal investigator: Krebs, Shelly J — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Krebs, Shelly J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.